The standard first-line treatment for metastatic colorectal cancer is fluorouracil-based chemotherapy plus anti–epidermal growth factor receptor/vascular endothelial growth factor (anti-EGFR/VEGF) therapy showing overall median survival of 29 to 30 months [2–3], with switching to a low-intensity or low-toxicity maintenance therapy in responding patients trying to reach a balance between the clinical efficacy and adverse effects (AEs) [4]. The gene discussed is VEGFA; the disease is metastatic colorectal cancer.